Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Brain, Behavior, and Immunity|June 19, 2015
Endocannabinoids drive the acquisition of an alternative phenotype in microgliaM Mecha, A Feliú, F J Carrillo-Salinas, et al.
Behavioural Pharmacology|April 13, 2004
Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male ratsE M Marco, L Pérez-Alvarez, E Borcel, et al.
Neurobiology of Disease|October 10, 2009
An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosisF Loría, S Petrosino, M Hernangómez, et al.
Brain, Behavior, and Immunity|December 25, 2018
The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microgliaM Mecha, N Yanguas-Casás, A Feliú, et al.
British Journal of Pharmacology|April 11, 2015
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosisA Feliú, M Moreno-Martet, M Mecha, et al.
Revista De Neurologia|October 31, 2006
[Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis]L Mestre, F Correa, F Docagne, et al.
British Journal of Pharmacology|September 25, 2007
CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategiesA Arévalo-Martín, D García-Ovejero, O Gómez, et al.
British Journal of Pharmacology|May 22, 2015
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosisL Mestre, M Redondo, F J Carrillo-Salinas, et al.
Molecular Psychiatry|December 9, 2015
Brain-borne IL-1 adjusts glucoregulation and provides fuel support to astrocytes and neurons in an autocrine/paracrine mannerA Del Rey, M Verdenhalven, A C Lörwald, et al.
Pageof 9